NT_1170x120_1-11-18

Issue 01-07-2019

Canada’s pharmacy sector holding strong

Canada’s pharmacy sector holding strong

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Looking ahead to 2019, the pharmacy business is poised to be more disrupted than ever before. Over the past 10 years, our members have successfully navigated a number of headwinds to their operating and regulatory environments, including price compression, regulatory

Putting patients first and encouraging innovation

Putting patients first and encouraging innovation

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. For much of 2018, capital markets for biotech investment were strong. Some 53 biotech companies went public with more than $5.4 billion in funding, putting the biotech industry on track for the second-best year for IPOs in a decade. And

Making the Rx markets more competitive again

Making the Rx markets more competitive again

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the

Making health care work better for patients

Making health care work better for patients

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too

Value-based contracts provide promise and potential

Value-based contracts provide promise and potential

There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the ­conversation.” Fortunately, the spirited national conversation about drug

Bartell’s stands apart among regional chains

Bartell’s stands apart among regional chains

SEATTLE — Founded in 1890, Bartell Drugs has maintained a leading position in the greater Seattle market by staying close to local consumers and continually developing new ways of addressing their changing needs. “My grandfather instilled in us the value of customer service,” says George Bartell, chairman of the 68-store retailer. “Serving the customer is

Chain Drug Review names Hartsig top merchant

Chain Drug Review names Hartsig top merchant

DEERFIELD, Ill. — Walgreens is continuing to transform its retail business, and one of the principal architects of the transformation is senior vice president and chief merchandising officer Joe Hartsig. In recognition of his contribution, the editors of Chain Drug Review have named Hartsig its 2018 Merchant of the Year. Hartsig, who joined Walgreens in

WBA tabs three global executives

WBA tabs three global executives

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) recently announced three global leadership appointments. Vineet Mehra will be joining WBA as global chief marketing officer. He will be based at corporate headquarters here and will report to WBA co-chief operating officers Ornella Barra and Alex Gourlay. As global CMO, Mehra will be responsible for the visioning,

Walgreens and Verily boost chronic care

Walgreens and Verily boost chronic care

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) and Verily, an Alphabet company, will be collaborating on multiple projects under a broad agreement aimed at improving health outcomes for patients with chronic conditions, while also lowering the cost of care. Walgreens will be a first-choice retail pharmacy development and commercialization partner to Verily, and the organizations